 Peter Kabos
Concepts (380)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 49 | 2024 | 1965 | 6.200 |
Why?
| | Receptors, Estrogen | 19 | 2024 | 387 | 3.290 |
Why?
| | Receptor, ErbB-2 | 12 | 2024 | 320 | 1.930 |
Why?
| | Receptors, Progesterone | 11 | 2020 | 325 | 1.370 |
Why?
| | Brain Neoplasms | 12 | 2023 | 1022 | 1.090 |
Why?
| | Keratin-5 | 6 | 2022 | 47 | 0.930 |
Why?
| | Triple Negative Breast Neoplasms | 6 | 2023 | 164 | 0.920 |
Why?
| | Estrogens | 7 | 2023 | 328 | 0.890 |
Why?
| | Biomarkers, Tumor | 7 | 2022 | 1059 | 0.880 |
Why?
| | Breast Neoplasms, Male | 3 | 2018 | 31 | 0.860 |
Why?
| | Stem Cells | 7 | 2006 | 559 | 0.790 |
Why?
| | Tetrahydronaphthalenes | 1 | 2021 | 32 | 0.780 |
Why?
| | Neoplasm Metastasis | 4 | 2020 | 544 | 0.780 |
Why?
| | Immunoprecipitation | 4 | 2020 | 161 | 0.740 |
Why?
| | Antineoplastic Agents, Hormonal | 6 | 2020 | 143 | 0.730 |
Why?
| | Benzodiazepines | 1 | 2021 | 122 | 0.730 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 62 | 0.730 |
Why?
| | Estrogen Receptor alpha | 3 | 2021 | 126 | 0.720 |
Why?
| | Brain Edema | 2 | 2023 | 61 | 0.720 |
Why?
| | Radiosurgery | 3 | 2023 | 318 | 0.700 |
Why?
| | Neurons | 7 | 2004 | 1345 | 0.700 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 176 | 0.670 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 2 | 2017 | 58 | 0.670 |
Why?
| | Leukocytes, Mononuclear | 2 | 2020 | 509 | 0.660 |
Why?
| | Gene Expression Profiling | 7 | 2020 | 1597 | 0.620 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2019 | 453 | 0.610 |
Why?
| | Neoplastic Stem Cells | 7 | 2020 | 336 | 0.600 |
Why?
| | Fanconi Anemia Complementation Group N Protein | 1 | 2017 | 5 | 0.600 |
Why?
| | Polyadenylation | 1 | 2017 | 38 | 0.600 |
Why?
| | Gene Expression Regulation, Neoplastic | 10 | 2022 | 1167 | 0.600 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2020 | 671 | 0.590 |
Why?
| | Carcinogenesis | 2 | 2020 | 182 | 0.590 |
Why?
| | Organoplatinum Compounds | 1 | 2016 | 41 | 0.590 |
Why?
| | Female | 51 | 2024 | 61564 | 0.590 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 1390 | 0.590 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 14 | 0.580 |
Why?
| | Fluorouracil | 1 | 2016 | 151 | 0.550 |
Why?
| | CD146 Antigen | 3 | 2021 | 41 | 0.540 |
Why?
| | Mitochondrial Proteins | 1 | 2017 | 226 | 0.530 |
Why?
| | Artifacts | 1 | 2016 | 125 | 0.530 |
Why?
| | Thrombocytopenia | 1 | 2016 | 185 | 0.500 |
Why?
| | MCF-7 Cells | 4 | 2020 | 111 | 0.500 |
Why?
| | Maytansine | 1 | 2014 | 13 | 0.500 |
Why?
| | Humans | 63 | 2024 | 118972 | 0.470 |
Why?
| | Cell Line, Tumor | 14 | 2020 | 2851 | 0.460 |
Why?
| | Tumor Microenvironment | 4 | 2021 | 454 | 0.460 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 794 | 0.460 |
Why?
| | Trastuzumab | 5 | 2023 | 92 | 0.450 |
Why?
| | RNA-Binding Proteins | 1 | 2016 | 371 | 0.450 |
Why?
| | Binding Sites | 1 | 2016 | 1224 | 0.440 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 195 | 0.440 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.430 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 1974 | 0.430 |
Why?
| | Homeodomain Proteins | 5 | 2018 | 468 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2021 | 900 | 0.410 |
Why?
| | MicroRNAs | 5 | 2016 | 637 | 0.410 |
Why?
| | RNA | 2 | 2016 | 833 | 0.400 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2023 | 360 | 0.400 |
Why?
| | Protein Kinase Inhibitors | 5 | 2021 | 811 | 0.400 |
Why?
| | Liver Neoplasms | 1 | 2015 | 527 | 0.400 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 667 | 0.400 |
Why?
| | Neoadjuvant Therapy | 3 | 2021 | 333 | 0.390 |
Why?
| | Estradiol | 3 | 2015 | 476 | 0.390 |
Why?
| | Mutation | 3 | 2021 | 3457 | 0.390 |
Why?
| | Progestins | 5 | 2020 | 77 | 0.360 |
Why?
| | Tamoxifen | 4 | 2018 | 198 | 0.360 |
Why?
| | Colorectal Neoplasms | 1 | 2016 | 628 | 0.360 |
Why?
| | Pyrimidines | 3 | 2018 | 382 | 0.360 |
Why?
| | Prognosis | 7 | 2021 | 3443 | 0.340 |
Why?
| | Hydrocephalus | 3 | 2023 | 81 | 0.340 |
Why?
| | Adenocarcinoma | 1 | 2015 | 812 | 0.340 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2020 | 91 | 0.330 |
Why?
| | Tumor Cells, Cultured | 5 | 2020 | 874 | 0.320 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 273 | 0.320 |
Why?
| | Signal Transduction | 5 | 2018 | 4709 | 0.310 |
Why?
| | Middle Aged | 15 | 2021 | 27617 | 0.310 |
Why?
| | Neoplasm Staging | 4 | 2021 | 1223 | 0.290 |
Why?
| | Helix-Loop-Helix Motifs | 2 | 2002 | 11 | 0.280 |
Why?
| | Astrocytes | 4 | 2023 | 177 | 0.280 |
Why?
| | Necrosis | 2 | 2019 | 230 | 0.280 |
Why?
| | Chondroitin Sulfate Proteoglycans | 2 | 2006 | 9 | 0.270 |
Why?
| | Cluster Analysis | 4 | 2019 | 481 | 0.270 |
Why?
| | Sequence Analysis, RNA | 2 | 2019 | 409 | 0.260 |
Why?
| | Neuroglia | 2 | 2003 | 157 | 0.260 |
Why?
| | Neoplasm Grading | 2 | 2017 | 258 | 0.260 |
Why?
| | Aged | 13 | 2023 | 19657 | 0.250 |
Why?
| | Mice, Inbred NOD | 5 | 2021 | 574 | 0.250 |
Why?
| | Aromatase Inhibitors | 2 | 2021 | 52 | 0.250 |
Why?
| | Carbolines | 1 | 2024 | 29 | 0.240 |
Why?
| | Progesterone | 3 | 2014 | 242 | 0.230 |
Why?
| | Animals | 25 | 2021 | 33381 | 0.230 |
Why?
| | Extracellular Matrix Proteins | 1 | 2004 | 133 | 0.230 |
Why?
| | Adult | 14 | 2021 | 31512 | 0.230 |
Why?
| | Aquaporin 4 | 2 | 2023 | 87 | 0.220 |
Why?
| | Keratin-17 | 1 | 2022 | 4 | 0.220 |
Why?
| | Mice | 17 | 2021 | 15520 | 0.220 |
Why?
| | Stromal Cells | 2 | 2020 | 102 | 0.220 |
Why?
| | Nerve Regeneration | 1 | 2002 | 53 | 0.220 |
Why?
| | Immunoconjugates | 1 | 2023 | 89 | 0.220 |
Why?
| | Tumor Suppressor Proteins | 2 | 2015 | 289 | 0.220 |
Why?
| | Mice, SCID | 4 | 2020 | 333 | 0.220 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 28 | 0.210 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 462 | 0.210 |
Why?
| | Medicare | 3 | 2023 | 663 | 0.210 |
Why?
| | Down-Regulation | 4 | 2015 | 627 | 0.210 |
Why?
| | Interleukin-13 Receptor alpha2 Subunit | 1 | 2021 | 6 | 0.210 |
Why?
| | Cyclins | 1 | 2002 | 82 | 0.200 |
Why?
| | Genetic Therapy | 1 | 2003 | 267 | 0.200 |
Why?
| | Gene Regulatory Networks | 2 | 2014 | 239 | 0.200 |
Why?
| | Piperazines | 1 | 2024 | 316 | 0.200 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2015 | 455 | 0.200 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2002 | 155 | 0.190 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2020 | 58 | 0.190 |
Why?
| | Cell Adhesion Molecules | 1 | 2021 | 180 | 0.190 |
Why?
| | RNA, Messenger | 3 | 2019 | 2657 | 0.190 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 35 | 0.190 |
Why?
| | Transcriptome | 2 | 2019 | 756 | 0.190 |
Why?
| | Pyridines | 1 | 2024 | 440 | 0.190 |
Why?
| | Antigens, Neoplasm | 1 | 2021 | 228 | 0.180 |
Why?
| | Meningeal Carcinomatosis | 1 | 2020 | 8 | 0.180 |
Why?
| | Hyaluronan Receptors | 4 | 2014 | 93 | 0.180 |
Why?
| | SEER Program | 1 | 2021 | 205 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 156 | 0.180 |
Why?
| | Retrospective Studies | 5 | 2023 | 12978 | 0.180 |
Why?
| | Aminopyridines | 1 | 2020 | 85 | 0.180 |
Why?
| | Carcinoma, Lobular | 1 | 2020 | 56 | 0.180 |
Why?
| | Gene Library | 2 | 2019 | 127 | 0.180 |
Why?
| | Repressor Proteins | 1 | 2002 | 377 | 0.180 |
Why?
| | Collagen | 2 | 2020 | 433 | 0.180 |
Why?
| | Disease-Free Survival | 2 | 2020 | 649 | 0.180 |
Why?
| | Aged, 80 and over | 3 | 2021 | 6561 | 0.180 |
Why?
| | Lymphatic Metastasis | 2 | 2017 | 307 | 0.170 |
Why?
| | Benzimidazoles | 1 | 2020 | 140 | 0.170 |
Why?
| | ErbB Receptors | 2 | 2020 | 569 | 0.170 |
Why?
| | Paclitaxel | 1 | 2020 | 195 | 0.170 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 52 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2017 | 740 | 0.160 |
Why?
| | beta Catenin | 1 | 2020 | 219 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2023 | 9342 | 0.160 |
Why?
| | RNA Polymerase III | 1 | 2017 | 25 | 0.150 |
Why?
| | Disease Progression | 4 | 2018 | 2490 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 80 | 0.150 |
Why?
| | Heterografts | 4 | 2020 | 130 | 0.150 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 187 | 0.150 |
Why?
| | 3' Untranslated Regions | 1 | 2017 | 142 | 0.150 |
Why?
| | Glioma | 3 | 2006 | 306 | 0.150 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 72 | 0.140 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 66 | 0.140 |
Why?
| | Pyrroles | 1 | 2017 | 191 | 0.140 |
Why?
| | Cell Proliferation | 5 | 2021 | 2275 | 0.140 |
Why?
| | Receptors, Androgen | 1 | 2017 | 134 | 0.140 |
Why?
| | Ovary | 1 | 2017 | 205 | 0.140 |
Why?
| | Ribosomal Proteins | 1 | 2015 | 68 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 93 | 0.130 |
Why?
| | Gene Expression | 2 | 2016 | 1489 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1166 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 982 | 0.130 |
Why?
| | Paracrine Communication | 1 | 2015 | 57 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 420 | 0.130 |
Why?
| | Fibroblasts | 1 | 2020 | 842 | 0.130 |
Why?
| | Pyrazoles | 1 | 2018 | 363 | 0.130 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 199 | 0.130 |
Why?
| | Hodgkin Disease | 1 | 2016 | 119 | 0.130 |
Why?
| | DNA Primers | 1 | 2016 | 533 | 0.130 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 576 | 0.130 |
Why?
| | Azepines | 1 | 2015 | 74 | 0.130 |
Why?
| | Obesity | 2 | 2018 | 2746 | 0.130 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 43 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 278 | 0.120 |
Why?
| | Peptides | 1 | 2020 | 879 | 0.120 |
Why?
| | Receptors, Steroid | 1 | 2014 | 54 | 0.120 |
Why?
| | Odds Ratio | 1 | 2017 | 996 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 417 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2017 | 3730 | 0.110 |
Why?
| | Apoptosis | 4 | 2017 | 2484 | 0.110 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1346 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1795 | 0.110 |
Why?
| | CD24 Antigen | 1 | 2012 | 21 | 0.110 |
Why?
| | Male | 8 | 2018 | 57801 | 0.110 |
Why?
| | Retinoids | 1 | 2012 | 32 | 0.110 |
Why?
| | Anthracyclines | 2 | 2023 | 41 | 0.110 |
Why?
| | United States | 4 | 2023 | 12555 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 969 | 0.110 |
Why?
| | RNA Interference | 1 | 2014 | 460 | 0.110 |
Why?
| | Taxoids | 2 | 2023 | 98 | 0.110 |
Why?
| | Doxorubicin | 3 | 2022 | 302 | 0.110 |
Why?
| | Comorbidity | 1 | 2017 | 1527 | 0.100 |
Why?
| | Small Molecule Libraries | 1 | 2012 | 80 | 0.100 |
Why?
| | Mitochondria | 1 | 2017 | 786 | 0.100 |
Why?
| | Genome, Human | 1 | 2014 | 387 | 0.100 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 160 | 0.100 |
Why?
| | Tumor Burden | 1 | 2012 | 274 | 0.100 |
Why?
| | Cell Differentiation | 3 | 2004 | 1753 | 0.100 |
Why?
| | Drug Discovery | 1 | 2012 | 124 | 0.100 |
Why?
| | Rats | 5 | 2017 | 5392 | 0.100 |
Why?
| | Logistic Models | 1 | 2016 | 1901 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2002 | 219 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2015 | 597 | 0.090 |
Why?
| | Protein Binding | 1 | 2016 | 1975 | 0.090 |
Why?
| | Dendritic Cells | 2 | 2004 | 442 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 39 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2220 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 770 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 462 | 0.090 |
Why?
| | BRCA2 Protein | 1 | 2009 | 44 | 0.090 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 356 | 0.090 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 51 | 0.090 |
Why?
| | Time Factors | 2 | 2020 | 6412 | 0.090 |
Why?
| | Thrombophilia | 1 | 2009 | 68 | 0.080 |
Why?
| | Receptors, CXCR4 | 2 | 2006 | 81 | 0.080 |
Why?
| | Quinolines | 2 | 2021 | 128 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1200 | 0.080 |
Why?
| | Brain | 2 | 2023 | 2490 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2006 | 4077 | 0.080 |
Why?
| | Proteoglycans | 2 | 2006 | 109 | 0.080 |
Why?
| | Risk Factors | 2 | 2020 | 9000 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 2 | 2002 | 2478 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 189 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 306 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2275 | 0.070 |
Why?
| | Aurora Kinase A | 2 | 2018 | 52 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1691 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2674 | 0.070 |
Why?
| | Cell Movement | 2 | 2015 | 896 | 0.070 |
Why?
| | Nervous System | 1 | 2006 | 66 | 0.070 |
Why?
| | Biopsy | 2 | 2020 | 1079 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2436 | 0.070 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 245 | 0.070 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 245 | 0.070 |
Why?
| | Mass Spectrometry | 2 | 2020 | 681 | 0.070 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2004 | 1 | 0.060 |
Why?
| | Infant, Premature, Diseases | 1 | 2006 | 93 | 0.060 |
Why?
| | Aggrecans | 1 | 2004 | 14 | 0.060 |
Why?
| | Lectins, C-Type | 1 | 2004 | 63 | 0.060 |
Why?
| | Cyclophosphamide | 2 | 2018 | 222 | 0.060 |
Why?
| | Glioblastoma | 2 | 2006 | 262 | 0.060 |
Why?
| | Adipose Tissue | 2 | 2018 | 606 | 0.060 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 91 | 0.060 |
Why?
| | Hemangioma, Cavernous, Central Nervous System | 1 | 2003 | 9 | 0.060 |
Why?
| | Cell Line | 2 | 2014 | 2707 | 0.060 |
Why?
| | Aromatase | 1 | 2023 | 31 | 0.060 |
Why?
| | Inhibitor of Differentiation Protein 2 | 1 | 2002 | 4 | 0.060 |
Why?
| | Inhibitor of Differentiation Protein 1 | 1 | 2002 | 7 | 0.060 |
Why?
| | Camptothecin | 1 | 2023 | 100 | 0.060 |
Why?
| | Pyramidal Tracts | 1 | 2002 | 20 | 0.060 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2003 | 56 | 0.060 |
Why?
| | Edema | 1 | 2023 | 124 | 0.060 |
Why?
| | Neurites | 1 | 2002 | 45 | 0.060 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2022 | 11 | 0.060 |
Why?
| | Sciatic Nerve | 1 | 2002 | 59 | 0.050 |
Why?
| | Vimentin | 1 | 2022 | 62 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 193 | 0.050 |
Why?
| | Transcription Factor HES-1 | 1 | 2002 | 4 | 0.050 |
Why?
| | Phenotype | 1 | 2010 | 3003 | 0.050 |
Why?
| | Neoplasms | 1 | 2015 | 2179 | 0.050 |
Why?
| | Frontal Lobe | 1 | 2002 | 148 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2002 | 100 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 109 | 0.050 |
Why?
| | Blotting, Western | 1 | 2004 | 1194 | 0.050 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1206 | 0.050 |
Why?
| | Fibroblast Growth Factors | 1 | 2002 | 175 | 0.050 |
Why?
| | Ependymoma | 1 | 2003 | 169 | 0.050 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2020 | 7 | 0.050 |
Why?
| | Cerebral Cortex | 1 | 2004 | 416 | 0.050 |
Why?
| | Nucleosomes | 1 | 2022 | 131 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 47 | 0.050 |
Why?
| | Hospitals, University | 1 | 2021 | 172 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 446 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2002 | 806 | 0.050 |
Why?
| | Nervous System Diseases | 1 | 2003 | 261 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2004 | 4908 | 0.050 |
Why?
| | Adherens Junctions | 1 | 2020 | 26 | 0.050 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 105 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 104 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 842 | 0.040 |
Why?
| | Immunotherapy | 1 | 2003 | 493 | 0.040 |
Why?
| | Mice, Nude | 2 | 2015 | 663 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2019 | 268 | 0.040 |
Why?
| | Cadherins | 1 | 2020 | 186 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 23 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2018 | 42 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 150 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 107 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2012 | 1158 | 0.040 |
Why?
| | Breast | 1 | 2018 | 140 | 0.040 |
Why?
| | Mastectomy | 1 | 2018 | 124 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 1171 | 0.040 |
Why?
| | Phenylthiohydantoin | 1 | 2017 | 40 | 0.040 |
Why?
| | Antigens, CD | 1 | 2020 | 460 | 0.040 |
Why?
| | Diarrhea | 1 | 2018 | 181 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2017 | 63 | 0.040 |
Why?
| | Ovariectomy | 1 | 2017 | 124 | 0.040 |
Why?
| | Area Under Curve | 1 | 2017 | 296 | 0.040 |
Why?
| | Nitriles | 1 | 2017 | 155 | 0.040 |
Why?
| | Benzamides | 1 | 2017 | 176 | 0.040 |
Why?
| | Fatigue | 1 | 2018 | 297 | 0.040 |
Why?
| | Steroids | 1 | 2017 | 153 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2012 | 1085 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 756 | 0.030 |
Why?
| | Cell Membrane | 1 | 2020 | 710 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 355 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2009 | 190 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 65 | 0.030 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 15 | 0.030 |
Why?
| | Postmenopause | 1 | 2017 | 305 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 493 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 356 | 0.030 |
Why?
| | Transcription Factors | 1 | 2002 | 1570 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 311 | 0.030 |
Why?
| | Software | 1 | 2019 | 613 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2014 | 25 | 0.030 |
Why?
| | Wnt-5a Protein | 1 | 2014 | 19 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2014 | 30 | 0.030 |
Why?
| | Argonaute Proteins | 1 | 2014 | 28 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2014 | 56 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 351 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1323 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2014 | 79 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2017 | 688 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 317 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1129 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2014 | 140 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 523 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2445 | 0.030 |
Why?
| | Acitretin | 1 | 2012 | 3 | 0.030 |
Why?
| | Miconazole | 1 | 2012 | 4 | 0.030 |
Why?
| | Isotretinoin | 1 | 2012 | 22 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 217 | 0.030 |
Why?
| | Stem Cell Transplantation | 2 | 2004 | 153 | 0.030 |
Why?
| | Biomarkers | 2 | 2017 | 3588 | 0.030 |
Why?
| | Luciferases | 1 | 2012 | 143 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 369 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3174 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2012 | 270 | 0.030 |
Why?
| | Tretinoin | 1 | 2012 | 116 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 3057 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 527 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4596 | 0.020 |
Why?
| | Diet | 1 | 2018 | 1153 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4196 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 395 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 625 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 618 | 0.020 |
Why?
| | Base Sequence | 1 | 2014 | 2159 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 2995 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 70 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1203 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1440 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2871 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 126 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2014 | 732 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2009 | 158 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2008 | 194 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1055 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2008 | 158 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2009 | 5255 | 0.020 |
Why?
| | Nestin | 1 | 2006 | 16 | 0.020 |
Why?
| | Chemokines, CXC | 1 | 2006 | 64 | 0.020 |
Why?
| | Laminin | 1 | 2006 | 68 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2006 | 80 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2006 | 69 | 0.020 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2006 | 87 | 0.020 |
Why?
| | Lasers | 1 | 2006 | 124 | 0.020 |
Why?
| | Drug Combinations | 1 | 2006 | 291 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 112 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2006 | 564 | 0.010 |
Why?
| | Injections, Intralesional | 1 | 2003 | 33 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 2002 | 65 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 56 | 0.010 |
Why?
| | Models, Neurological | 1 | 2004 | 216 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 344 | 0.010 |
Why?
| | Infant, Premature | 1 | 2006 | 480 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 551 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 774 | 0.010 |
Why?
| | Survival Rate | 1 | 2003 | 1720 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2006 | 3171 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 5690 | 0.010 |
Why?
| | Vaccination | 1 | 2003 | 1222 | 0.010 |
Why?
| | Prospective Studies | 1 | 2006 | 6471 | 0.010 |
Why?
| | Infant | 1 | 2006 | 8293 | 0.010 |
Why?
|
|
Kabos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|